Last $7.05 USD
Change Today -0.12 / -1.67%
Volume 312.5K
INO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Open
$7.18
Previous Close
$7.17
Day High
$7.24
Day Low
$6.95
52 Week High
03/20/14 - $15.56
52 Week Low
02/24/15 - $6.33
Market Cap
427.2M
Average Volume 10 Days
594.8K
EPS TTM
$-0.44
Shares Outstanding
60.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INOVIO PHARMACEUTICALS INC (INO)

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

71 Employees
Last Reported Date: 03/17/14
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $852.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.0K
Chief Operating Officer
Total Annual Compensation: $409.8K
Chief Medical Officer
Total Annual Compensation: $414.3K
Compensation as of Fiscal Year 2013.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc. Presents at 22nd Annual Emerald Groundhog Day Investment Forum, Feb-05-2015 02:45 PM

Inovio Pharmaceuticals, Inc. Presents at 22nd Annual Emerald Groundhog Day Investment Forum, Feb-05-2015 02:45 PM. Venue: Radisson Blu - Warwick Hotel, Philadelphia, Pennsylvania, United States.

Inovio Pharmaceuticals, Inc. Appoints Mark Stephen Gelder as Vice President of Clinical Development

Inovio Pharmaceuticals, Inc. announced it has appointed Mark Stephen Gelder, M.D. as Vice President, Clinical Development. Dr. Gelder will be responsible for planning and executing Inovio's clinical development strategy for its immunotherapies against human papillomavirus (HPV)-caused cervical cancer and dysplasia. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer. Dr. Gelder's previous experience includes therapeutic oncology programs at Pfizer, Wyeth and Bayer.

Inovio Pharmaceuticals, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM

Inovio Pharmaceuticals, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: J. Joseph Kim, Chief Executive Officer, President, Director and Member of Finance Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $7.05 USD -0.12

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $10.12 USD +0.80
Argos Therapeutics Inc $9.08 USD +0.04
Dynavax Technologies Corp $19.72 USD +0.91
Genocea Biosciences Inc $8.35 USD -0.47
GenVec Inc $3.22 USD +0.03
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.5x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit www.inovio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.